Industry Leader: This Biotech Company Receives Rating From This Analyst
HC Wainwright & Co. Maintains Buy on Can Fite Biofarma, Lowers Price Target to $18.
In a recent development, New York-based investment bank, HC Wainwright & Co, has maintained its "Buy" rating on Can Fite Biofarma, but has revised its price target to $18. This decision comes as part of the bank's ongoing analysis and monitoring of the biopharmaceutical market.
The adjustment in the price target by HC W…